
10x Genomics Cash Flow 2025-2011 | TXG
Brief overview of 10x Genomics's cash generation
This overview follows the five latest available annual observations in the 2021–2025 interval.
Operating cash flow recovered from negative territory and reached $136.1 million. Core operations returned to generating cash.
Positive operating cash flow appeared only 2 times out of five; a stable cash profile has not formed.
Operating cash margin reached 21.2% versus -4.4% initially. Revenue converted into cash more effectively.
Estimated working capital fell by $37.2 million, releasing resources equal to about 5.8% of latest revenue.
Cash flow takeaway
There is no unconditional cash flow signal for 10x Genomics. Repeatability of OCF and the quality of its use remain important.
Annual Cash Flow 10x Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
136 M | 6.66 M | -15.2 M | -33.6 M | -21.4 M | -218 M | 34.6 M | -76.4 M | -10.7 M | - | - | - | - | - | - |
Depreciation & Amortization |
36.2 M | 35.9 M | 35.5 M | 25.4 M | 21.1 M | 14 M | 7.07 M | 3.9 M | 4.3 M | - | - | - | - | - | - |
Accounts Payables |
12.7 M | 12.9 M | 15.7 M | 21.6 M | 17.4 M | 4.71 M | 13 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
47 M | 87.9 M | 115 M | 104 M | 85.3 M | 51.2 M | 33.4 M | - | - | - | - | - | - | - | - |
Total Inventories |
56.3 M | 83.1 M | 73.7 M | 81.6 M | 60 M | 30 M | 15.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow 10x Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
26.1 M | 95.3 M | 52.1 M | 34.4 M | - | - | -15.7 M | - | - | -4.12 M | - | - | -37.8 M | -20.8 M | - | - | -962 K | -4.08 M | - | -87.7 M | -32.1 M | -2.58 M | - | 27.9 M | 13.4 M | 9.32 M | - | -25.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
9.96 M | 26.1 M | 15.8 M | 8.02 M | - | - | 9.19 M | - | - | 6.48 M | - | - | 12.7 M | 6.19 M | - | - | 9.64 M | 4.75 M | - | 10.1 M | 6.5 M | 3.19 M | - | 4.22 M | 2.18 M | 1.04 M | - | 3.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
17.4 M | 18.1 M | 15.9 M | 10.1 M | 26.2 M | 21.2 M | 20.2 M | - | - | 29.3 M | 21.6 M | - | 26.7 M | 19 M | 17.4 M | 17 M | 16.2 M | 15.6 M | 4.71 M | 4.71 M | 4.71 M | 4.71 M | 13 M | 13 M | 13 M | 13 M | 8.79 M | 8.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
39 M | 43.8 M | 50 M | 52.5 M | 83.5 M | 91.2 M | 91.3 M | - | - | 77.9 M | 104 M | - | 76.2 M | 76.5 M | 85.3 M | 78.4 M | 59.7 M | 57.4 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | 28.1 M | 28.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
53.5 M | 62 M | 69 M | 74.7 M | 94 M | 88.3 M | 83.2 M | - | - | 82.3 M | 81.6 M | - | 70.6 M | 63.7 M | 60 M | 51.1 M | 44.1 M | 38.5 M | 30 M | 30 M | 30 M | 30 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 8.57 M | 8.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company 10x Genomics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Health information services sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
OptimizeRx Corporation
OPRX
|
$ 6.37 | 0.47 % | $ 118 M | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
So-Young International
SY
|
$ 1.94 | -1.02 % | $ 151 M | ||
|
HealthEquity
HQY
|
$ 104.13 | 2.85 % | $ 8.97 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
American Well Corporation
AMWL
|
$ 10.77 | -3.41 % | $ 173 M | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Zhongchao
ZCMD
|
$ 1.06 | -9.4 % | $ 3.62 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Progyny
PGNY
|
$ 31.37 | 1.98 % | $ 2.67 B | ||
|
Phreesia
PHR
|
$ 11.14 | 2.67 % | $ 665 M | ||
|
GoodRx Holdings
GDRX
|
$ 3.22 | 3.21 % | $ 1.15 B | ||
|
Schrödinger
SDGR
|
$ 15.12 | -1.11 % | $ 1.11 B | ||
|
Omnicell
OMCL
|
$ 41.4 | -3.83 % | $ 1.9 B | ||
|
Health Catalyst
HCAT
|
$ 2.16 | 0.93 % | $ 151 M | ||
|
HealthStream
HSTM
|
$ 29.53 | 2.36 % | $ 886 M | ||
|
Evolent Health
EVH
|
$ 3.3 | -11.76 % | $ 377 M | ||
|
Teladoc Health
TDOC
|
$ 9.18 | -1.92 % | $ 1.62 B | ||
|
Veeva Systems
VEEV
|
$ 207.91 | 3.33 % | $ 34 B |